Six decades after the serendipitous discovery of chlorpromazine as an antipsychotic and four decades after the launch of clozapine, the first atypical or second generation antipsychotic, psychopharmacology has arrived at an important crossroad. It is clear that pharmacological research and pharmaceutical development must now focus on complementary or even alternative mechanisms of action to address unmet medical needs, i.e. poorly treated domains of schizophrenia, improved acceptance by patients, better adherence to medication, safety in psychoses in demented patients, and avoiding cardiac and metabolic adverse effects. The first completely novel mechanisms evolving from our insights into the pathophysiology of psychotic disorders, especially the role of glutamatergic mechanisms in schizophrenia, are now under development, and further principles are on the horizon. This situation, in many respects similar to that when the initial second-generation antipsychotics became available, can be rewarding for all. Preclinical and clinical researchers now have the opportunity to confirm their hypotheses and the pharmaceutical industry may be able to develop really novel classes of therapeutics. When we were approached by the publishers of the Handbook of Experimental Pharmacology to prepare a new volume on antipsychotics, our intention was to capture both, the accumulated preclinical and clinical knowledge about current antipsychotics as well as prospects for new and potentially more specific antischizophrenia principles. These efforts should be based on the pathophysiology of the diseases and the affected neurotransmitter systems. Since preclinical research on antipsychotic compounds is only reliable when intimately linked through translational aspects to clinical results, we decided to include clinical science as well. It turned out that that this endeavor could not be covered by a single volume. We thank the editorial board and the publishers for supporting our decision to prepare two volumes: Current Antipsychotics and Novel Antischizophrenia Treatments. These topics cannot really be separated from one another and should be seen as a composite entity despite the somewhat arbitrary separation of contributions into two volumes. The continuing challenges of developing improved and safer antipsychotic medications remain of concern and are discussed in the first volume. The new opportunities for the field to develop and license adjunctive treatments for the negative symptoms and cognitive deficits that are treated inadequately by existing compounds have been incentivized recently and provide the focus for the second volume. We hope these collective contributions will facilitate the development of improved treatments for the full range of symptomatology seen in the group of schizophrenias and other major psychotic disorders. Gerhard Gross, Ludwigshafen, Germany Mark A. Geyer, La Jolla, CA This volume will try to put current therapy - achievements, shortcomings, remaining medical needs - and emerging new targets into the context of increasing knowledge regarding the genetic and neurodevelopmental contributions to the pathophysiology of schizophrenia. Some of the chapters will also deal with respective experimental and clinical methodology, biomarkers, and translational aspects of drug development. Non-schizophrenia indications will be covered to some extent, but not exhaustively.

Pharmaceutical manufacture is very exacting - for example, drugs must be uniform in size, shape, efficacy, bioavailability, and safety. The presence of different polymorphs in drug production is a serious problem, since different polymorphs differ in bioavailability, solubility, dissolution rate, chemical and physical stability, melting point, color, filterability, density, and flow properties. Fine Particles in Medicine and Pharmacy discusses particle size, shape, and composition and how they determine the choice of polymorph of a drug.

Here is a new book on methods and issues in clinical research. Its objectives can be summarized in three points. 1. Integrate medical and statistical components of clinical research. 2. Do justice to the operational and practical requirements of clinical research. 3. Give space to the ethical implications of methodological issues in clinical research. The book ends with a brief description of the drug development process and the phases of clinical development.

A comprehensive treatment of the characterisation techniques used in investigating inorganic and organic molecules that interact with biomolecules is presented to the reader in a clear fashion. The work consists of two parts: (i) synthetic aspects of metallointercalators along with targeting and improving transport and (ii) the various techniques that are used for probing their interactions, such as; DNA-NMR, PGSE-NMR, DNA ESI-MS, Linear and Circular Dichroism, Fluorescence Spectroscopy, Confocal Microscopy, Viscosity, TGA and dialysis, Microarrays, biological analysis. Chapters are devoted to the synthesis and the techniques used to study the interactions of inorganic complexes with biomolecules. Considerably detailed examples are used to help illustrate the application of these techniques. This book is a useful resource for an array of inorganic and organic advanced undergraduate and graduate courses and for researchers in drug discovery.

This book is intended to serve as a resource for analysts in developing and troubleshooting sample preparation methods. These are critical activities in providing accurate and reliable data throughout the lifecycle of a drug product. This book is divided into four parts: * Part One covers dosage form and diluent properties that impact sample preparation of pharmaceutical dosage forms and the importance of sampling considerations in generating data representative of the drug product batch. * Part Two reviews specific sample preparation techniques typically used with pharmaceutical dosage forms. * Part Three discusses sample preparation method development for different types of dosage forms including addressing drug excipient interactions and post extraction considerations, as well as method validation and applying Quality by Design (QbD) principles to sample preparation methods. * Part Four examines additional topics in sample preparation including automation, investigating aberrant potency results, green chemistry considerations for sample preparation and the ideal case where no sample preparation is required for sample analysis.

Established as a classic text on nuclear chemistry and pharmacy, Fundamentals of Nuclear Pharmacy has been thoroughly revised with new information added covering innovations in imaging technology and clinical applications in the field. The Sixth Edition also eliminates outdated information from previous editions on radiopharmaceuticals now discontinued from the market. Dr. Gopal B. Saha's books have continually been praised for their clarity and accuracy while setting new standards for making complex theoretical concepts readily understandable to the reader. Like past editions, this book is intended to be used as a textbook on nuclear chemistry and pharmacy for nuclear medicine residents and students and as a reference book for nuclear medicine physicians and radiologists. New sections in the Sixth Edition include: * PET/CT and SPECT/CT * Digital Imaging * Exploratory IND * Nanoparticle Imaging * Treatment of liver cancer with 90Y-TheraSpheres and 90Y-SIR-Spheres * Treatment of Non-Hodgkin's lymphoma with 131I-Bexxar

This volume tries to put current therapy - achievements, shortcomings, remaining medical needs - and emerging new targets into the context of increasing knowledge regarding the genetic and neurodevelopmental contributions to the pathophysiology of schizophrenia. Some of the chapters also deal with respective experimental and clinical methodology, biomarkers, and translational aspects of drug development. The volume concentrates on reviewing the ongoing research attempting to identify novel treatments for the cognitive deficits and negative symptoms of schizophrenia, which are not treated adequately by current antipsychotic medications.

This comprehensive and interdisciplinary handbook provides a bird's-eye view of two centuries of research on secondary metabolites of the two large Solanales families, Solanaceae and Convolvulaceae. In this book they're arranged according to their biosynthetic principles, while the occurrence and chemical structures of almost all known individual secondary metabolites are covered, which are found in hundreds of wild as well as cultivated solanaceous and convolvulaceous species.

Macromolecular drugs hold the promise of becoming new therapeutics for several major disorders, including cancer and cardiovascular disease. This incredible potential is explored in Macromolecular Drug Delivery, a volume which gives a wide-ranging overview of contemporary methods used in the field, and which addresses the limitations presented by a lack of safe and efficient drug delivery strategies. Chapters offer information on both in vitro and in vivo methods of macromolecular delivery, thus appealing to a broad scientific audience. Composed in the highly successful Methods in Molecular Biology (TM) series format, each chapter contains a brief introduction, step-by-step methods, a list of necessary materials, and a Notes section which shares tips on troubleshooting and avoiding known pitfalls. Comprehensive and cutting-edge, Macromolecular Drug Delivery offers a platform for interdisciplinary collaboration, which should provide opportunities for new discoveries at the interface between disciplines. Ultimately, this cooperation will lead to the use of macromolecular drugs as novel diagnostic tools and, even more importantly, as a means to revolutionize the way we view and treat diseases.

After more than twenty years of use Good Laboratory Practice, or GLP, has attained a secure place in the world of testing chemicals and other "test items" with regard to their safety for humans and the environment. Gone are the days when the GLP regulations were hotly debated amongst scientists in academia and industry and were accused of stifling flexibility in, imaginative approaches to, and science-based conduct of, all kinds of studies concerned with toxic effects and other parameters important for the evaluation and assessment of products submitted for registration and permission to market. The GLP regulations have developed from rules on how to exactly document the planning, conduct and reporting of toxicity studies to a quality system for the management of a multitude of study types, from the simple determination of a physical/chemical parameter to the most complex field studies or ecotoxicology studies. At the same time the term "Good Laboratory Practice" has become somewhat of a slogan with the aim to characterise any reliably conducted laboratory work.

Antibiotics are truly miracle drugs. As a class, they are one of the only ones that actually cure disease as opposed to most drugs that only help relieve symptoms or control disease. Since bacteria that cause serious disease in humans are becoming more and more resistant to the antibiotics we have today, and because they will ultimately become resistant to any antibiotic that we use for treatment or for anything else, we need a steady supply of new antibiotics active against any resistant bacteria that arise. However, the antibiotics marketplace is no longer attractive for large pharmaceutical companies, the costs of development are skyrocketing because of ever more stringent requirements by the regulatory agencies, and finding new antibiotics active against resistant strains is getting harder and harder. These forces are all combining to deny us these miracle drugs when we need them the most. I provide a number of possible paths to shelter from this perfect storm.

What drives a scientist to edit a book on a speci c scienti c subject such as chiral mechanisms in separation methods? Until December 2005, the journal Analytical Chemistry of the American Chemical Society (Washington, DC) had an A-page section that was dedicated to simple and clear presentations of the most recent te- niques or the state of the art in a particular eld or topic. The "A-page" section was prepared for a broad audience of chemists including industrial professionals, s- dents as well as academics looking for information outside their eld of expertise. 1 Daniel W. Armstrong, one of the editors of this journal and a twenty-year+ long friend, invited me to present my view on chiral recognition mechanisms in a simple and clear way in an "A-page" article. In 2006, the "A-page" section was maintained as the rst articles at the beginning of each rst bi-monthly issue but the pagination was no longer page distinguished from the regular research articles published by the journal. During the time between the invitation and the submission, the A-page section was integrated into the rest of the journal and the article appeared as (2006) Anal Chem (78):2093-2099.

The book "Nanocosmetics and nanomedicines: new approaches for skin care" contains a summary of the most important nanocarriers for skin delivery. Although "nanocosmetics" is a subject widely commented in the academy and the beauty industry, a book covering the skin care treatments using nanotechnological approaches with cosmetics and nanomedicines is still missing, therefore the need for this publication. This book is divided in three parts: The first one (Part A) is devoted to a brief review on the main topics related to the skin delivery and to the introduction of the subject "nanocosmetics". The second part (Part B) presents different types of nanocarriers applied as skin delivery systems for cosmetics or drugs. The last part (Part C) shows a wide range of applications of nanotechnology on the skin care area as well as on dermatocosmetic and dermatological fields.

Drug discovery originating in Africa has the potential to provide significantly improved treatment of endemic diseases such as malaria, tuberculosis and HIV/AIDS. This book critically reviews the current status of drug discovery research and development in Africa, for diseases that are a major threat to the health of people living in Africa. Compiled by leading African and international experts, this book presents the science and strategies of modern drug discovery. It explores how the use of natural products and traditional medicines can benefit from conventional drug discovery approaches, and proposes solutions to current technological, infrastructural, human resources, and economic challenges, which are presented when attempting to engage in full-scale drug discovery. Topics addressed are varied; from African medicinal plants to marine bioprospecting, pharmacogenetics and the use of nanotechnology. This book brings together for the first time a collection of strategies and techniques that need to be considered when developing drugs in an African setting. It is an unprecedented and truly international effort, highlighting the remarkable effort made so far in the area of drug discovery research by African scientists, and scientists from other parts of the world working on African health problems.

Animal cell technology is becoming an increasingly important part of biotechnology and many products are now used in human health care and for veterinary applications. However, there are many times more products actually in the developmental pipelines of the biotechnology industry, including various phases of clinical trials. The Proceedings of the 15th Meeting of the European Society for Animal Cell Technology (Tours, France, September 1997) presents the actual current state as well as New Developments and Applications in Animal Cell Technology for the benefit of society. These Proceedings represent both the current state and applications of animal cell technology and the way the technology is expanding into new areas to give a unique insight into new products and applications for human and animal health care.

New Antisense Strategies: Chemical Synthesis of RNA Oligomers, by Junichi Yano und Gerald E. Smyth Development and Modification of Decoy Oligodeoxynucleotides for Clinical Application, by Mariana Kiomy Osako, Hironori Nakagami und Ryuichi Morishita Modulation of Endosomal Toll-Like Receptor-Mediated Immune Responses by Synthetic Oligonucleotides, by Ekambar R. Kandimalla und Sudhir Agrawal Delivery of Nucleic Acid Drugs, by Yan Lee und Kazunori Kataoka Aptamer: Biology to Applications, by Yoshikazu Nakamura Development and Clinical Applications of Nucleic Acid Therapeutics, by Veenu Aishwarya, Anna Kalota und Alan M. Gewirtz

It was an extraordinary pleasure for me, as the secretary general, to organise, with my collaborators, this Second International Symposium on Antibiotic Resistance in the Castle of Smolenice in Czechoslovakia. We all appreciated many offers all participants must have spent to attend this Symposium and we were glad to do our best to prepare this meeting in a suitable and convenient way. We gathered in Smolenice Castle after the significant International Congress on Che motherapy in September 1973 in Athens. We had the chance of getting acquainted, on that world-wide forum, with the latest information about bacterial resistance to anti biotics. It was possible at that Congress to outline main topics of interest in the field of bacterial resistance to antibiotics which then have been placed on the programme of the subsequent Smolenice Symposium. Undoubtedly, enzymatic mechanisms by which bacteria can inactivate older and newer antibacterial drugs and which can be transmitted and spread among bacterial strains, have both medical as well as theoretical priority. Dealing specially with Pseudomonas aeruginosa is highly urgent at present from the clinical, hygienical and genetical point of view. We have realised that antibiotics have ceased to be "magic bullets" which hit the microorganisms without discrimination. Today we urgently consider the question what should be done in the area of "antibiotic policy" to preserve the effectiveness of antibiotics for the future.

Carl Edward Sagan's (1934-1996) one of the famous quotation was "Who are we? We find that we live on an insignificant planet of a humdrum star lost in a galaxy tucked away in some forgotten corner of a universe in which there are far more galaxies than people." From past to date, well-known molecules, enzymes, proteins, lipids and carbohydrates are studied in the pathogenesis of several diseases both as a diagnostic/prognostic biomarker and therapeutic agent. The underlying mechanism of unexplained diseases and failure of therapies are frequently studied with well-known biomarkers, but remain unclear in many cases. As Dr. Sagan said other keys are still waiting to be known in some forgotten corner of a body universe, we find strength to propose that one of them can be the growth factor with cytokine activity named "Midkine" This book summarizes the extensive up-to-date literature overeview with the lastest work of experts about midkine in a detailed format that conveys its role as both a pathologic factor and therapeutic agent.

Many of the reactions and compounds involved in metabolism are almost iden tical in the different groups of living organisms. They are known as primary me tabolic reactions and primary metabolic products. In addition, however, a wide variety of biochemical pathways are characteristic of only a few species of organ isms, of single "chemical races", or even of a certain stage of differentiation of specialized cells. Such pathways are collectively referred to as "secondary metab olism", and the compounds formed are called "secondary products". Secondary products are frequently revealed by their color, smell, or taste. They are responsi ble for the flavor of most foodstuffs and beverages and for the color and fragrance of flowers and fruits. Many of them are part of the materia medica, e. g. , alka loids, cardiac glycosides, antibiotics, or compounds acting as hormones. Others are used in the industry, e. g. , rubber, tannins, and cellulose. This book treats the organization and significance of biosynthesis, storage, transformation, and degradation of the most important groups of secondary pro ducts in microorgimisms, plants, arid animals. It shows that the formation of sec ondary products is a common characteristic of specialized cells brought about by the action of special enzymes encoded by specific genetic material.

How do firms jointly develop open information infrastructures? To answer this question, this book draws on the results of a longitudinal research project covering the development of the pharmaceutical distribution industry in China from 2004 to 2012, focusing on the emergence and subsequent evolution of industry-wide information infrastructures. How do firms delimit areas of proprietary innovation in open innovation projects? How do firms coordinate, initiate, negotiate and implement the development of innovative infrastructures? How do processes and practices within firms enable and constrain such collective efforts? - This book provides answers to these questions and draws conclusions regarding the challenges and new capabilities that firms will need in a world in which participation in the building of open information infrastructures becomes a necessary task for commercial organizations.

The specific topic, Isoquinolines And Beta-Carbolines As Neurotoxins And Neuroprotectants New Perspectives In ParkinsonS Disease Therapy, was chosen in light of accumulating neurobiological evidence indicating that, in addition to exogenous neurotoxins (e.g., 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine MPTP]), endogenous compounds may play an important role in the most common neurodegenerative disorders (e.g., Parkinsons disease). Two groups of amine related compounds, which appeared chemically like MPTP, were detected in human brain and cerebrospinal fluid (CSF): "ss"-carbolines (BCs) and tetrahydroisoquinolines (TIQs). These are heterocyclic compounds formed endogenously from phenylalanine/tyrosine (TIQs) and tryptophan, tryptamine, and 5-hydroxytryptamine (BCs), respectively and exert a wide spectrum of psychopharmacological and behavioral effects. The TIQs and BCs may bind to their own high affinity sites on neuronal membranes associated with or located close to the receptors of neurotransmitters. Research on TIQs and BCs is stimulated also by their possible role in pathological conditions, especially parkinsonism and alcoholism. Recently, clinical interest has been spurred by their role as neuroprotective, and even neurorestorative, anticonvulsant and antiaddictive, substances.

In this book we are going to summarize, for the first time, the results from behavioral, neurochemical and molecular experiments, which demonstrate a wide spectrum of TIQs and BCs effects - from their rather mild neurotoxic actions to the important neuroprotective and antiaddictive properties.

Additionally, the recent results of experimental studies "in vivo" have allowed a much better understanding and simultaneous comparison of the neurochemical and molecular mechanisms underlying the neuroprotective and neurotoxic actions of endogenous TIQs and BCs and have pointed to the possibility of their therapeutic applications in neurodegenerative diseases such as Parkinson's disease."